Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative treatments for skin diseases. Founded in 2018, Verrica has quickly established itself in the dermatology sector, particularly in the treatment of conditions such as molluscum contagiosum. The company’s flagship product, VP-102, is a unique topical therapy that utilises a proprietary formulation to effectively target viral skin infections. This innovative approach sets Verrica apart in a competitive market, positioning it as a key player in dermatological therapeutics. With a commitment to advancing patient care, Verrica Pharmaceuticals continues to make significant strides in the industry, aiming to improve the quality of life for those affected by challenging skin conditions.
DitchCarbon Score
How does Verrica Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Verrica Pharmaceuticals Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Verrica Pharmaceuticals Inc.'s reported carbon emissions
Verrica Pharmaceuticals Inc., headquartered in the US, currently does not have publicly available carbon emissions data for recent years, as indicated by the absence of specific emissions figures. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of data suggests that Verrica Pharmaceuticals may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the pharmaceutical industry increasingly prioritises sustainability, it will be essential for Verrica to establish clear emissions reduction goals and commitments to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Verrica Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
